KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Capital Expenditures for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 4.16% year-over-year to $1.2 million, compared with a TTM value of $6.5 million through Dec 2025, down 52.76%, and an annual FY2025 reading of $6.5 million, down 52.76% over the prior year.
  • Capital Expenditures was $1.2 million for Q4 2025 at Recursion Pharmaceuticals, up from $243000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $24.9 million in Q3 2022 and bottomed at -$28.5 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $3.1 million, with a median of $2.5 million recorded in 2025.
  • The sharpest move saw Capital Expenditures soared 2738.6% in 2021, then crashed 738.19% in 2022.
  • Year by year, Capital Expenditures stood at $4.5 million in 2021, then plummeted by 738.19% to -$28.5 million in 2022, then skyrocketed by 73.85% to -$7.4 million in 2023, then surged by 117.43% to $1.3 million in 2024, then decreased by 4.16% to $1.2 million in 2025.
  • Business Quant data shows Capital Expenditures for RXRX at $1.2 million in Q4 2025, $243000.0 in Q3 2025, and $3.2 million in Q2 2025.